KPC(600422) 海通国际证券·2025-04-25 08:36Investment Rating - The report maintains an "Outperform" rating for the company [4][7]. Core Insights - In 2024, the company achieved revenue of 8.40 billion RMB, a decrease of 0.34% year-on-year, while net profit attributable to shareholders was 648 million RMB, an increase of 19.86% year-on-year [4][7]. - The company adjusted its earnings per share (EPS) forecast for 2025 and 2026 to 0.97 RMB and 1.15 RMB respectively, with a new forecast for 2027 EPS at 1.38 RMB [4][7]. - The target price is set at 21.34 RMB, reflecting a 12% decrease based on an industry average valuation with a 2025 price-to-earnings (PE) ratio of 22X [4][7]. - Oral dosage forms showed stable performance with revenue of 3.69 billion RMB in 2024, up 1.18% year-on-year, while injectable products faced challenges with revenue of 539 million RMB, down 49.09% year-on-year [4][7]. - The company is undergoing deep restructuring and brand/channel remodeling, with a five-year strategic plan released under the guidance of China Resources Group [4][7]. Financial Data Summary - The company’s revenue projections for the next few years are as follows: 9.25 billion RMB in 2025, 10.17 billion RMB in 2026, and 11.22 billion RMB in 2027, reflecting growth rates of 10.1%, 10.0%, and 10.3% respectively [2][4]. - Net profit attributable to shareholders is projected to be 733 million RMB in 2025, 871 million RMB in 2026, and 1.04 billion RMB in 2027, with growth rates of 13.1%, 18.7%, and 19.9% respectively [2][4]. - The company’s return on equity (ROE) is expected to improve from 12.3% in 2024 to 15.0% in 2027 [2][4].